Total reported value
$435.1M
Reporting period: 2026-03-31 · Number of holdings: 42
GREAT POINT PARTNERS LLC disclosed 42 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $435.1M and a quarterly turnover rate of 92.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "G"
Trim IMVT
-27.3% -$5.5M
Add NKTR
+50.2% $13.9M
Trim APGE
0.0% $3.3M
Add VOR
+27.7% $13.3M
Trim AMLX
0.0% $3.2M
Trim CGEM
-52.7% -$2.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics INC | Stock-Other | 7.23% | -1.92% | — | |
| 2 | VOR | Vor Biopharma INC | Stock-Other | 7.18% | +1.37% | +27.73% | |
| 3 | ✓ | Zura Bio LTD | Stock-Other | 5.77% | -0.71% | +10.48% | |
| 4 | AMLX | Amylyx Pharmaceuticals INC | Stock-Other | 5.59% | -1.26% | — | |
| 5 | IBRX | Immunitybio INC | Stock-Healthcare | 5.29% | +5.29% | NEW | |
| 6 | NKTR | Nektar Therapeutics | Stock-Other | 5.23% | +2.34% | +50.17% | |
| 7 | ✓ | Stock-Other | 5.00% | +5.00% | NEW | ||
| 8 | ALMS | Alumis INC | Stock-Other | 4.33% | +4.33% | NEW | |
| 9 | DRUG | Bright Minds Biosciences INC | Stock-Other | 3.69% | +3.69% | NEW | |
| 10 | ANNX | Annexon INC | Stock-Other | 3.18% | +3.18% | NEW | |
| 11 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 3.12% | -0.47% | -1.55% | |
| 12 | IMVT | Immunovant INC | Stock-Other | 3.11% | -3.07% | -27.25% | |
| 13 | JBIO | Jade Biosciences INC | Stock-Other | 3.11% | -0.92% | +19.62% | |
| 14 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.40% | -0.56% | +0.02% | |
| 15 | ZBIO | Zenas Biopharma INC | Stock-Other | 2.35% | +2.35% | NEW | |
| 16 | NGNE | Neurogene INC | Stock-Other | 2.32% | -0.02% | +42.86% | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.14% | +2.14% | NEW | |
| 18 | CLYM | Climb Bio INC | Stock-Other | 2.10% | +0.83% | +36.20% | |
| 19 | ORKA | Oruka Therapeutics INC | Stock-Other | 2.07% | +0.27% | — | |
| 20 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 2.00% | -0.94% | — | |
| 21 | VERA | Vera Therapeutics INC | Stock-Other | 1.84% | +1.84% | NEW | |
| 22 | EVMN | Evommune INC | Stock-Other | 1.72% | -0.08% | — | |
| 23 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 1.70% | +1.70% | NEW | |
| 24 | CMPX | Compass Therapeutics INC | Stock-Other | 1.64% | +1.64% | NEW | |
| 25 | SCYXEUR | Scynexis INC | Stock-Other | 1.59% | +1.59% | NEW | |
| 26 | PALI | Palisade Bio INC | Stock-Other | 1.37% | +1.37% | NEW | |
| 27 | CNTX | Context Therapeutics INC | Stock-Other | 1.35% | -0.88% | -52.21% | |
| 28 | RLMD | Relmada Therapeutics INC | Stock-Other | 1.35% | +1.35% | NEW | |
| 29 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.24% | -0.35% | +26.29% | |
| 30 | UNCY | Unicycive Therapeutics INC | Stock-Other | 1.20% | -0.29% | — | |
| 31 | TENX | Tenax Therapeutics INC | Stock-Other | 1.20% | +1.20% | NEW | |
| 32 | PMN | Promis Neurosciences INC | Stock-Other | 1.08% | +1.08% | NEW | |
| 33 | CGEM | Cullinan Therapeutics INC | Stock-Other | 0.98% | -1.15% | -52.68% | |
| 34 | IMMX | Immix Biopharma INC | Stock-Other | 0.73% | +0.73% | NEW | |
| 35 | RZLT | Rezolute INC | Stock-Other | 0.67% | -0.06% | — | |
| 36 | PHVS | Pharvaris N.V. | Stock-Other | 0.54% | -0.20% | — | |
| 37 | HUMA | Humacyte INC | Stock-Other | 0.52% | +0.52% | NEW | |
| 38 | GALT | Galectin Therapeutics INC | Stock-Other | 0.51% | +0.51% | NEW | |
| 39 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.43% | -0.30% | — | |
| 40 | ALKS | Alkermes plc | Stock-Healthcare | 0.41% | +0.41% | NEW | |
| 41 | AVXL | Anavex Life Sciences CORP | Stock-Other | 0.37% | +0.37% | NEW | |
| 42 | IRD | Opus Genetics INC | Stock-Other | 0.34% | +0.34% | NEW |
Performance for Q3 2026
+17.8%
Performance Last 4 Quarters
+104.9%
Based on 69% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 42 | $435.1M | 93 | |
| 2025-12-31 | 29 | $308.4M | 100 | |
| 2025-09-30 | 30 | $242.5M | 100 | |
| 2025-06-30 | 26 | $153.8M | 0 | |
| 2025-03-31 | 32 | $188.8M | 100 | |
| 2024-12-31 | 26 | $212.2M | 0 | |
| 2024-09-30 | 30 | $339.8M | 0 | |
| 2024-06-30 | 33 | $522.0M | 0 | |
| 2024-03-31 | 35 | $641.6M | 0 | |
| 2023-12-31 | 34 | $586.7M | 0 | |
| 2023-09-30 | 42 | $549.0M | 0 | |
| 2023-06-30 | 40 | $510.8M | 0 | |
| 2023-03-31 | 44 | $509.3M | 0 | |
| 2022-12-31 | 42 | $510.2M | 0 | |
| 2022-09-30 | 40 | $415.3M | 0 | |
| 2022-06-30 | 35 | $417.0M | 0 | |
| 2022-03-31 | 30 | $413.8M | 0 | |
| 2021-12-31 | 36 | $450.1M | 0 | |
| 2021-09-30 | 36 | $429.5M | 0 | |
| 2021-06-30 | 30 | $476.7M | 68 | |
| 2021-03-31 | 28 | $483.9M | 86 | |
| 2020-12-31 | 33 | $615.7M | 100 | |
| 2020-09-30 | 34 | $1.1B | 49 | |
| 2020-06-30 | 36 | $1.3B | 75 | |
| 2020-03-31 | 36 | $957.1M | 64 | |
| 2019-12-31 | 37 | $1.1B | 100 | |
| 2019-09-30 | 43 | $1.1B | 56 | |
| 2019-06-30 | 31 | $900.8M | 90 | |
| 2019-03-31 | 41 | $1.0B | 66 | |
| 2018-12-31 | 42 | $791.2M | 77 | |
| 2018-09-30 | 30 | $641.7M | 64 | |
| 2018-06-30 | 44 | $721.6M | 82 | |
| 2018-03-31 | 38 | $673.4M | 77 | |
| 2017-12-31 | 39 | $586.1M | 85 | |
| 2017-09-30 | 39 | $514.0M | 71 | |
| 2017-06-30 | 41 | $558.2M | 67 | |
| 2017-03-31 | 39 | $503.5M | 79 | |
| 2016-12-31 | 35 | $486.8M | 51 | |
| 2016-09-30 | 35 | $392.1M | 79 | |
| 2016-06-30 | 39 | $349.2M | 76 | |
| 2016-03-31 | 33 | $278.7M | 53 | |
| 2015-12-31 | 25 | $238.3M | 55 | |
| 2015-09-30 | 37 | $252.8M | 67 | |
| 2015-06-30 | 34 | $256.5M | 88 | |
| 2015-03-31 | 35 | $227.2M | 75 | |
| 2014-12-31 | 28 | $207.8M | 93 | |
| 2014-09-30 | 40 | $232.8M | 70 | |
| 2014-06-30 | 38 | $224.8M | 70 | |
| 2014-03-31 | 38 | $191.5M | 88 | |
| 2013-12-31 | 29 | $141.6M | 92 | 144915N269562K336106P |
| 2013-09-30 | 32 | $144.1M | 0 | 144915N236106P302318X |
Great Point Partners LLC's most significant position changes for 2026-03-31: New buy: Immunitybio INC (IBRX); New buy: ; Sold out: Disc Medicine INC (IRON); Sold out: Rapt Therapeutics INC (RAPT); New buy: Alumis INC (ALMS).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NKTR | Nektar Therapeutics | +2.3% | +50.17% | Add |
| 2 | VOR | Vor Biopharma INC | +1.4% | +27.73% | Add |
| 3 | CLYM | Climb Bio INC | +0.8% | +36.20% | Add |
| 4 | ORKA | Oruka Therapeutics INC | +0.3% | — | Unchanged |
| 5 | NGNE | Neurogene INC | 0% | +42.86% | Add |
| 6 | RZLT | Rezolute INC | -0.1% | — | Unchanged |
| 7 | EVMN | Evommune INC | -0.1% | — | Unchanged |
| 8 | PHVS | Pharvaris N.V. | -0.2% | — | Unchanged |
| 9 | UNCY | Unicycive Therapeutics INC | -0.3% | — | Unchanged |
| 10 | AVTX | Avalo Therapeutics INC | -0.3% | — | Unchanged |
| 11 | SLN | Silence Therapeutics Plc-adr | -0.4% | +26.29% | Add |
| 12 | 4XC1 | Kalvista Pharmaceuticals INC | -0.5% | -1.55% | Trim |
| 13 | CTNM | Contineum Therapeutics Inc-a | -0.6% | +0.02% | Add |
| 14 | ✓ | Zura Bio LTD | -0.7% | +10.48% | Add |
| 15 | CNTX | Context Therapeutics INC | -0.9% | -52.21% | Trim |
| 16 | JBIO | Jade Biosciences INC | -0.9% | +19.62% | Add |
| 17 | EPRX | Eupraxia Pharmaceuticals INC | -0.9% | — | Unchanged |
| 18 | CGEM | Cullinan Therapeutics INC | -1.2% | -52.68% | Trim |
| 19 | AMLX | Amylyx Pharmaceuticals INC | -1.3% | — | Unchanged |
| 20 | APGE | Apogee Therapeutics INC | -1.9% | — | Unchanged |
| 21 | IMVT | Immunovant INC | -3.1% | -27.25% | Trim |
| 22 | IBRX | Immunitybio INC | — | NEW | New buy |
| 23 | ✓ | — | NEW | New buy | |
| 24 | IRON | Disc Medicine INC | — | EXIT | Sold out |
| 25 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 26 | ALMS | Alumis INC | — | NEW | New buy |
| 27 | SLNOEUR | Soleno Therapeutics INC | — | EXIT | Sold out |
| 28 | DRUG | Bright Minds Biosciences INC | — | NEW | New buy |
| 29 | DNTH | Dianthus Therapeutics INC | — | EXIT | Sold out |
| 30 | ANNX | Annexon INC | — | NEW | New buy |
| 31 | ZBIO | Zenas Biopharma INC | — | NEW | New buy |
| 32 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 33 | FULC | Fulcrum Therapeutics INC | — | EXIT | Sold out |
| 34 | UPB | Upstream Bio INC | — | EXIT | Sold out |
| 35 | VERA | Vera Therapeutics INC | — | NEW | New buy |
| 36 | LBRX | Lb Pharmaceuticals INC | — | NEW | New buy |
| 37 | CMPX | Compass Therapeutics INC | — | NEW | New buy |
| 38 | SCYXEUR | Scynexis INC | — | NEW | New buy |
| 39 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 40 | PALI | Palisade Bio INC | — | NEW | New buy |
| 41 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 42 | TENX | Tenax Therapeutics INC | — | NEW | New buy |
| 43 | PMN | Promis Neurosciences INC | — | NEW | New buy |
| 44 | IMMX | Immix Biopharma INC | — | NEW | New buy |
| 45 | SANA | Sana Biotechnology INC | — | EXIT | Sold out |
| 46 | HUMA | Humacyte INC | — | NEW | New buy |
| 47 | GALT | Galectin Therapeutics INC | — | NEW | New buy |
| 48 | ALKS | Alkermes plc | — | NEW | New buy |
| 49 | AVXL | Anavex Life Sciences CORP | — | NEW | New buy |
| 50 | IRD | Opus Genetics INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0001750852
Total reported value
$435.1M
124 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001867040
Total reported value
$435.1M
3 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001903320
Total reported value
$435.2M
70 stks
2024-03-31
Stale — no recent filing
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000019481
Total reported value
$362.5M
450 stks
2026-03-31
1 of the top 5 holdings overlap, including Immunitybio INC
CIK 0000078003
Total reported value
$238.8M
21 stks
2026-03-31
1 of the top 5 holdings overlap
CIK 0001596468
Total reported value
$442.5M
115 stks
2026-03-31
1 of the top 5 holdings overlap, including Amylyx Pharmaceuticals INC